Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

October 17, 2018 Editor CEO Interview, Healthcare Comments Off on Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., discusses cannabinoid-based drug pipeline.

tetra logo

 

Discover Tomorrow’s Winning Stocks!
Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered directly to your inbox.
Your privacy is our priority. Your email address will never be sold or shared with anyone else.

 

 

Guy Chamberland

 

 

 

 

 

Tetra Bio-Pharma (TSX: TBP) (OTC: TBPMF) CEO Guy Chamberland, Ph.D., shares update on Tetra’s Cannabinoid-based drug pipeline as opioid alternative.

Investor Presentation Deck

Tetra Investor Presentation




Related Articles

Healthcare

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

October 4, 2019 Editor Healthcare, Investor Presentations Comments Off on Hoth Therapeutics, Inc. (NASDAQ: HOTH) Next Super Stock Investor Conference presentation 9/26/2019

Hoth Therapeutics, Inc. (NASDAQ: HOTH) Discover Tomorrow’s Winning Stocks! Thank you for subscribing. Something went wrong. Get our latest stock reports before everyone else! Actionable news, and breakout stocks w multi-bagger upside potential — delivered […]

Healthcare

CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

September 9, 2019 Editor Healthcare, Newsmakers Comments Off on CytoDyn (OTC: CYDY) Announces FDA Clearance to Proceed with Phase 2 Study of Leronlimab (PRO 140) and Regorafenib as a Combination Therapy for Metastatic Colorectal Cancer

VANCOUVER, Washington, Sept. 09, 2019 — CytoDyn Inc. (otc.qb:CYDY), (“CytoDyn” or the “Company”), a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic indications, announced today that […]

Healthcare

Hoth Therapeutics (NASDAQ: HOTH) to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

September 6, 2019 Editor Healthcare, Newsmakers Comments Off on Hoth Therapeutics (NASDAQ: HOTH) to Present at the H.C. Wainwright 21st Annual Global Investment Conference and RESI 2019 Boston Conference

NEW YORK, Sept. 6, 2019  — Hoth Therapeutics, Inc. (NASDAQ: HOTH) a biopharmaceutical company focused on unique targeted therapeutics for patients suffering from indications such as atopic dermatitis–also known as eczema–as well as dermatological and chronic wound disorders, […]